|
PAREXEL INTERNATIONAL ANNOUNCES ACQUISITION OF HERON GROUP LTD,
A LEADING COMMERCIALIZATION CONSULTANCY
|
Stark contrasts can be found in almost every aspect of healthcare, most notably as it regards access to treatment. Adding to the complexity, global healthcare reforms present a driving, yet uncertain, force prompting flux in stakeholder roles and decision-making. Consequently, new drugs and treatments are developed in an environment where commercial planning for access requires the same strategic and scientific rigor used to obtain proof of efficacy.
HERON is an evidence-based life sciences consultancy providing commercial decision support throughout the product/portfolio lifecycle. With expertise and methodologies that align evidence development and economic evaluation with pricing, reimbursement, and market access planning, HERON is unique in its ability to realize product value and commercial opportunity at any point in your decision-making process.